Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.